Featured Research

from universities, journals, and other organizations

Marker Predicts Pancreatic Cancer Outcome After Surgery, Surgeon Finds

Date:
June 24, 2007
Source:
Thomas Jefferson University
Summary:
Scientists found further evidence supporting the ability of a protein to predict how well a patient with advanced pancreatic cancer will do after surgery, chemotherapy and radiation.

A team of researchers, led by surgeons at the Kimmel Cancer Center at Jefferson in Philadelphia, has found further evidence supporting the ability of a protein to predict how well a patient with advanced pancreatic cancer will do after surgery, chemotherapy and radiation. The levels of the protein CA 19-9 in the blood can be used to determine the need for further therapy, they say.

Adam Berger, M.D., assistant professor of surgery at Jefferson Medical College of Thomas Jefferson University, and his co-workers examined CA 19-9 levels and the survival of 385 patients with advanced pancreatic cancer who were treated with surgery and subsequent chemotherapy and radiation. They found that those patients whose post-operative CA 19-9 level exceeded 180 U/ml did much worse than those with lower levels.

In fact, at least half of those whose CA 19-9 level was higher than 180 U/ml lived for approximately nine months, while half of those whose levels were 180 or below lived more than twice as long, about 21 months. After three years, about 30 percent of those with levels 180 or under were still alive, while virtually none of the patients with levels above 180 remained alive. He reports his team’s findings June 23, 2007 at the semi-annual meeting of the Radiation Therapy Oncology Group (RTOG) in Philadelphia.

“We think that it is a very sensitive predictor of response to chemotherapy and radiation after surgery,” says Dr. Berger.

The main goal of the multicenter trial was to compare pancreatic cancer surgery patients who received two different types of chemotherapy – 5FU or gemcitabine – along with radiation. It was designed to look at CA 19-9 levels and survival after surgery as a secondary goal. Patients submitted blood samples prior to chemotherapy, which were analyzed for CA 19-9. Overall, 385 patients had levels that could be analyzed.

According to Dr. Berger, a post-surgery CA 19-9 level of 180 or less translated to a 72 percent reduction in death in patients treated with additional chemotherapy and radiation for pancreatic cancer compared to those with levels above 180.

While CA 19-9 is a well established tumor marker for pancreatic cancer, he notes, “These results allow us to stratify individuals for other therapies. If a person is operated on and has potentially curative surgery, but four to six weeks after surgery has a CA 19-9 level above 180, he or she should probably have a different treatment than what was given in this trial. They should probably have prolonged chemotherapy and hold off a little longer on radiation.”

While CA 19-9 is elevated in most patients with advanced pancreatic cancer, its use as a cancer marker is not foolproof. It may also be elevated in other cancers, conditions and diseases, such as colorectal cancer, lung cancer and pancreatitis, for example.

“The findings make a strong case for everyone to have CA 19-9 scores checked after surgery,” he says. “These should be followed regularly.” In addition, he notes, other researchers are studying whether the rate of change in CA 19-9 can predict survival. Future trials may involve examining the predictive value of lower CA 19-9 scores.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Marker Predicts Pancreatic Cancer Outcome After Surgery, Surgeon Finds." ScienceDaily. ScienceDaily, 24 June 2007. <www.sciencedaily.com/releases/2007/06/070622163919.htm>.
Thomas Jefferson University. (2007, June 24). Marker Predicts Pancreatic Cancer Outcome After Surgery, Surgeon Finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/06/070622163919.htm
Thomas Jefferson University. "Marker Predicts Pancreatic Cancer Outcome After Surgery, Surgeon Finds." ScienceDaily. www.sciencedaily.com/releases/2007/06/070622163919.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins